BIOGEN INC. Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount
BIOGEN INC. (BIIB) reported Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount of 100.00 thousand shares for the 12-month period ending 2011-12-31, per its 10-K filed 2012-02-03.
Discontinued › Income Statement › Earnings Per Share
us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount · last filed 2012-02-03
- BIOGEN INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2011-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- BIOGEN INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2011-06-30 was 0.00 shares, a 100.00% decline year-over-year.
- BIOGEN INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2011-03-31 was 1.00M shares, a 83.87% decline year-over-year.
- BIOGEN INC. antidilutive securities excluded from computation of earnings per share, amount for the quarter ending 2010-09-30 was 6.20M shares, a 45.61% decline year-over-year.
- BIOGEN INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2011 was 100.00K shares, a 98.08% decline from fiscal 2010.
- BIOGEN INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2010 was 5.20M shares, a 53.98% decline from fiscal 2009.
- BIOGEN INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2009 was 11.30M shares, a 26.97% increase from fiscal 2008.
- BIOGEN INC. antidilutive securities excluded from computation of earnings per share, amount for fiscal 2008 was 8.90M shares.
| Period end | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 3 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 6 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 9 month | Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount 12 month |
|---|---|---|---|---|
| 2011-12-31 | 100.00K shares 10-K · filed 2012-02-03 | |||
| 2011-09-30 | 0.00 shares 10-Q · filed 2011-10-28 | 100.00K shares 10-Q · filed 2011-10-28 | ||
| 2011-06-30 | 0.00 shares 10-Q · filed 2011-07-26 | 200.00K shares 10-Q · filed 2011-07-26 | ||
| 2011-03-31 | 1.00M shares 10-Q · filed 2011-04-21 | |||
| 2010-12-31 | 5.20M shares 10-K · filed 2012-02-03 | |||
| 2010-09-30 | 6.20M shares 10-Q · filed 2011-10-28 | 6.40M shares 10-Q · filed 2011-10-28 | ||
| 2010-06-30 | 7.20M shares 10-Q · filed 2011-07-26 | 6.60M shares 10-Q · filed 2011-07-26 | ||
| 2010-03-31 | 6.20M shares 10-Q · filed 2011-04-21 | |||
| 2009-12-31 | 11.30M shares 10-K · filed 2012-02-03 | |||
| 2009-09-30 | 11.40M shares 10-Q · filed 2010-10-26 | 10.10M shares 10-Q · filed 2010-10-26 | ||
| 2009-06-30 | 9.00M shares 10-Q · filed 2010-07-20 | 8.90M shares 10-Q · filed 2010-07-20 | ||
| 2008-12-31 | 8.90M shares 10-K · filed 2011-02-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |